Abstract
Aim:
RNA interference (RNAi) has been proposed as a potential treatment for cancer, but the lack of cellular targets limits its use in cancer gene therapy. No current technology has achieved direct tumor-specific gene silencing using RNAi. In the present study we attempt to develop a tumor-specific RNAi system using the human telomerase reverse transcriptase (hTERT) promoter; furthermore, we analyzed its inhibitive effect on Bcl-2 expression.
Methods:
The vectors containing a small hairpin RNA (shRNA) to target exogenous reporters [firefly luciferase and enhanced green fluorescent protein (EGFP)] and endogenous gene (Bcl-2) were constructed. Luciferase expression was determined by dual luciferase assay. Reverse transcription-polymerase chain reaction (RT-PCR), fluorescence microscopy and fluorescence-activated cell sorting (FACS) were used to measure EGFP expression. Inhibition of Bcl-2 was evaluated by RT-PCR and Western blotting. Cell proliferation and viability were measured by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. FACS was used to analyze the cell cycle distribution profile.
Results:
We showed that with the hTERT promoter directly driving shRNA transcription, expression of the exogenous reporters (LUC and EGFP) in tumor cells, but not normal cells, was specifically inhibited in vitro. The hTERT promoter-driven shRNA also depressed the expression of Bcl-2. Inhibition of Bcl-2 did not affect cell proliferation, but increased the chemosensitivity of HeLa cells to 5-fluorouracil.
Conclusion:
The present study describes an efficient RNAi system for gene silencing that is specific to tumor cells using the hTERT promoter. Suppression of Bcl-2 by using this system sensitized HeLa cells to 5–fluorouracil. This system may be useful for RNAi therapy.
Similar content being viewed by others
Article PDF
References
Wall NR, Shi Y . Small RNA: can RNA interference be exploited for therapy? Lancet 2003; 362: 1401–3.
Sui G, Soohoo C, Affar B, Gay F, Shi Y, Forrester WC, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 5515–20.
Brummelkamp TR, Bernards R, Agami R . A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550–3.
Robinson R . RNAi therapeutics: how likely, how soon? PLoS Biol 2004; 2: E28.
Hannon GJ, Rossi JJ . Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371–8.
Gou D, Narasaraju T, Chintagari NR, Jin N, Wang P, Liu L . Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucleic Acids Res 2004; 32: 134.
Tiscornia G, Tergaonkar V, Galimi F, Verma IM . CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci USA 2004; 101: 7347–51.
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T . Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494–8.
Cioca D, Aoki Y, Kiyosawa K . RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 2003; 10: 125–33.
Zeng Y, Yi R, Cullen BR . MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003; 100: 9779–84.
Xia H, Mao Q, Paulson HL, Davidson BL . SiRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006–10.
Komata T, Kanzawa T, Kondo Y, Kondo S . Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002; 21: 656–63.
Jacob D, Davis JJ, Zhang L, Zhu H, Teraishi F, Fang B . Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther 2005; 12: 109–15.
Song JS, Kim HP, Yoon WS, Lee KW, Kim MH, Kim KT et al. Adenovirus-mediated suicide gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter induced apoptosis of ovarian cancer cell line. Biosci Biotechnol Biochem 2003; 67: 2344–50.
Groot-Wassink T, Aboagye EO, Wang Y, Lemoine NR, Keith WN, Vassaux G . Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res 2004; 64: 4906–11.
Casillas MA, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO . Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 2003; 316: 57–65.
Seo E, Abei M, Wakayama M, Fukuda K, Ugai H, Murata T, et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res 2005; 65: 546–52.
Kuo PL, Hsu YL, Lin TC, Lin CC . The antiproliferative activity of prodelphinidin B-2 3′-O-gallate from green tea leaf is through cell cycle arrest and Fas-mediated apoptotic pathway in A549 cells. Food Chem Toxicol 2005; 43: 315–23.
Gross A, McDonnell JM, Korsmeyer SJ . BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899–911.
Nicolson NL, Talpaz M, Nicolson GL . Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia. Gene 1996; 169: 173–8.
Sarac S, Akyol MU, Kanbur B, Poyraz A, Akyol G, Yilmaz T, et al. Bcl-2 and LMP1 expression in nasopharyngeal carcinomas. Am J Otolaryngol 2001; 22: 377–82.
Khabir A, Ghorbel A, Daoud J, Frikha M, Drira MM, Laplanche A, et al. Similar BCL-X but different BCL-2 levels in the age groups of North African nasopharyngeal carcinomas. Cancer Detect Prev 2003; 27: 250–5.
Lopes de Menezes DE, Hu Y, Mayer LC . Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. J Exp Ther Oncol 2003; 3: 72–82.
Rudin CM, Kozloff M, Hoffman PC, Edelman MJ, Karnauskas R, Tomek R, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004; 22: 1110–7.
Lima RT, Martins LM, Guimaraes JE, Sambade C, Vasconcelos MH . Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther 2004; 11: 309–16.
Author information
Authors and Affiliations
Additional information
Project supported by the Fourth Key Subject Foundation of Shanghai Municipal Education Commission (ZDXK2001).
Rights and permissions
About this article
Cite this article
Huang, Sl., Wu, Y., Yu, H. et al. Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in Hela cells. Acta Pharmacol Sin 27, 242–248 (2006). https://doi.org/10.1111/j.1745-7254.2006.00247.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00247.x
Keywords
This article is cited by
-
A novel conditional gene silencing method using a tumor-specific and heat-inducible siRNA system
Journal of Industrial Microbiology and Biotechnology (2016)
-
Dual silencing of Bcl-2 and Survivin by HSV-1 vector shows better antitumor efficacy in higher PKR phosphorylation tumor cells in vitro and in vivo
Cancer Gene Therapy (2015)
-
Gene therapy of pancreatic cancer targeting the K-Ras oncogene
Cancer Gene Therapy (2012)
-
Dual bio-responsive gene delivery via reducible poly(amido amine) and survivin-inducible plasmid DNA
Biotechnology Letters (2010)
-
Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors
Molecular Therapy (2009)